24083-12-3

Basic information

• Product Name: Benzaldehyde, 3-(octyloxy)-
• CAS NO: 24083-12-3
• Molecular Formula: C15H22O2
• Molecular Weight: 234.338
• Mol File: 24083-12-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 3-(octyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 3-(octyloxy)-(24083-12-3)
• EPA Substance Registry System: Benzaldehyde, 3-(octyloxy)-(24083-12-3)

Safety Data

• Hazardous Substances Data: 24083-12-3(Hazardous Substances Data)

Upstream product

• 111-85-3 n-chlorooctane 
• 100-83-4 meta-hydroxybenzaldehyde 
• 111-87-5 octanol 
• 111-83-1 1-bromo-octane 

Downstream Products

• 77113-60-1 5-(3-(octyloxy)benzyl)pyrimidine-2,4-diamine 
• 307498-46-0 3-hydroxy-4-(3-octyloxy-phenyl)-butyric acid 
• 307498-43-7 1-(3-octyloxy-phenyl)-pent-4-en-2-ol 
• 307498-40-4 (3-octyloxy-phenyl)-acetaldehyde 
• 307498-37-9 1-((E)-2-Methoxy-vinyl)-3-octyloxy-benzene 
• 77113-65-6 (Z)-2-Methoxymethyl-3-(3-octyloxy-phenyl)-acrylonitrile 

Relevant articles and documents

Organic soluble indigoids derived from 3-hydroxybenzaldehyde for N-type organic field-effect transistor (OFET) applications

Two new series of organic soluble indigoids 7-7′-dialkoxyindigoids (2a, 2b) and 4,4′-dibromo-7,7′-dialkoxyindigoids (3a, 3b) (alkoxy = n-butoxy and n-octyloxy) were synthesized starting from the inexpensive 3-hydroxybenzaldehyde. The indigoids were solubl

Bicyclic heteroamatic compounds useful as LH agonists

The invention relates to a bicyclic heteroaromatic derivative compound according to general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1is NR5R6, OR5, SR5or R7; R5and R6are independently selected from H, (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, alkyl(1-8C)carbonyl, (6-14C)arylcarbonyl, (6-14C)aryl or (4-13C)heteroaryl, or R5and R6together are joined in a (2-7C)heterocloalkyl ring; R7is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl, R2is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)alkylthio, (1-8C)(di)alkylamino, (1-8C)alkoxy, (2-8C)alkenyl, or (2-8C)alkynyl; R3is (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, or (6-14C)aryl or (4-13C)heteroaryl, both optionally substituted with one or more substituents selected from (1-8C)alkyl, (1-8C)(di)alkylamino or (1-8C)alkoxy; X is S, O or N(R4); R4is H, (1-8C)alkyl, (1-8C)alkylcarbonyl, (6-14C)arylcarbonyl or (6-14C)aryl(1-8C)alkyl; Y is CH or N; Z is NH2or OH; A is S, N(H), N(R9), O or a bond; R9can be selected from the same groups as described for R2and B is N(H), O or a bond. The compounds of the invention have LH receptor activating activity and can be used in fertility regulating therapies.

Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines

-